Search Results
Your search for world matches 4350 pages
Showing 2601 - 2650CAR T-Cell Immunotherapy Named Advance of the Year in ASCO’s Clinical Cancer Advances 2018
A new and unique new way to treat cancer—chimeric antigen receptor (CAR) T-cell therapy—is poised to transform the outlook for children and adults with certain otherwise incurable cancers. ASCO named this type of adoptive-cell immunotherapy the Advance of the Year in its annual...
Israel Cancer Research Fund Appoints National Executive Director
Mark A. Israel, MD, a pediatric oncologist, translational scientist, and a recognized leader in cancer research has been appointed National Executive Director of the Israel Cancer Research Fund (ICRF), a nonprofit organization dedicated solely to funding cancer research in Israel. Dr. Israel joins ...
Former President and Director of Fred Hutchinson Cancer Research Center, Robert W. Day, MD, Dies at 87
ROBERT W. DAY, MD, the longest-serving President and Director of Fred Hutchinson Cancer Research Center and the leader who brought into being its campus overlooking Seattle’s South Lake Union, died in his Seattle home on January 6, 2018 of lung cancer. He was 87. “It is a tragic loss for all of...
The Telltale Heart: A Surgeon’s Memoir
We don’t feel our liver or pancreas working, but we all feel our hearts beating—the drumbeat of our mortality since we all have a finite number of heartbeats from birth to death. And unlike with most other organs, we are painfully aware of how fragile this mighty muscle can be. About 610,000 people ...
Internationally Renowned Prostate Cancer Expert Gerald E. Hanks, MD, Dies
FROM WILHELM RÖNTGEN’S groundbreaking discovery of x-rays in 1895, the history of radiotherapy has been rich with colorful paradigm-changing researchers and physicians who over the past century have transformed the field into one of the pillars of cancer treatment. One such trailblazer who...
A Neuroscientist Examines Intact Minds Adrift in Damaged Brains and Bodies
Understanding what consciousness is, and why and how it evolved, is perhaps the greatest mystery known to science. With its 100 billion or so neurons and a processing rate of about 4 billion bits per second, the human brain is a miraculously complicated entity, much of which is still under...
Second Global AYA Cancer Congress Highlights Research Advances and the Global Burden of Cancer Among Young Adults
This past December, nearly 400 medical professionals from a variety of fields—including medical oncology, palliative care, science, nursing, social work, and psychology—and 23 countries traveled to Atlanta, to attend the 2nd Global Adolescent & Young Adult (AYA) Cancer Congress. The 3-day...
Ursula Matulonis, MD, Named Brock-Wilson Family Chair at Dana-Farber Cancer Institute
Ursula Matulonis, MD, has been named the first incumbent of the Brock-Wilson Family Chair at Dana-Farber Cancer Institute (Dana-Farber). The newly established Chair was created to advance gynecologic oncology research and support a highly dedicated faculty member at Dana-Farber. Dr. Matulonis is...
Mary Beckerle, PhD, Honored by National Cancer Institute
Mary Beckerle, PhD, Chief Executive -Officer and Director of Huntsman Cancer Institute at the University of Utah, is this year’s recipient of the Alfred G. Knudson Award in Cancer Genetics from the National Cancer Institute (NCI). The prestigious award is named after Alfred G. Knudson, MD, PhD, a...
CancerLinQ® Partners With Leading Global Life Sciences Nonprofit
CANCERLINQ LLC and DIA (Drug Information Association), a global nonprofit association of health-care product development professionals, recently announced that they have entered into a programmatic partnership. Under the agreement, DIA will offer the scientific expertise of its members from the...
2018 ASCO Annual Meeting Call for Abstracts: Submit by February 13
ASCO INVITES you to submit an abstract for the 2018 ASCO Annual Meeting. Submit an abstract by February 13, 2018, at 11:59 PM (EST) to be considered for presentation or publication at this year’s Annual Meeting, to be held June 1–5 in Chicago, Illinois. The 2017 ASCO Annual Meeting attracted...
Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2019. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2018. Additionally, five members were...
Preserving Sexual Function in Women Treated for Cancer
“There is huge potential to positively influence a patient’s experience and outcomes” by addressing concerns about sexual function after cancer treatment early in the course of treatment planning, Stacy Tessler Lindau, MD, MA, stated in her keynote address at the 11th Annual Oncofertility...
Celebrating the Life of Jimmie Holland, MD
The oncology community mourns the sudden passing of Jimmie C. Holland, MD, who died on December 24, 2017, at the age of 89. Dr. Holland’s achievements over her 40-year career are legend. They include the founding of the subspecialty of psycho-oncology, the establishment of a full-time Psychiatry...
Study Finds Gene-Expression Profile Testing for Breast Cancer Less Cost-Effective in Real-World Practice
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by scientists from Georgetown Lombardi Comprehensive Cancer Center. Their study, published by Chandler et al in the Journal...
Oncology World Mourns the Loss of Jimmie C. Holland, MD, Founder, Field of Psycho-Oncology
Jimmie C. Holland, MD, died suddenly on December 24, 2017, at the age of 89 years. Dr. Holland was the Attending Psychiatrist and Wayne E. Chapman Chair at Memorial Sloan Kettering (MSK) Cancer Center and Professor of Psychiatry, Weill Medical College of Cornell University in New York....
Is Medical Assistance in Dying Compassionate Care?
Suicidal ideation while receiving end-of-life cancer care is not unusual but can often be reversed by palliative and psychosocial oncology interventions. That said, there are patients who, even after intensive interventions, request medical assistance in dying. Physician-assisted death has been a...
Durvalumab Consolidation After Chemoradiotherapy Improves Progression-Free Survival in Stage III Non–Small Cell Lung Cancer
As reported by Scott J. Antonia, MD, PhD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues in The New England Journal of Medicine, an interim analysis of the phase III -PACIFIC trial showed improved progression-free survival with the programmed cell death protein 1 (PD-1) ...
Durvalumab Consolidation After Chemoradiotherapy Improves Progression-Free Survival in Stage III Non–Small Cell Lung Cancer
As reported by Scott J. Antonia, MD, PhD, of the H. Lee Moffitt Cancer Center and Research Institute, and colleagues in The New England Journal of Medicine, an interim analysis of the phase III -PACIFIC trial showed improved progression-free survival with the programmed cell death protein 1 (PD-1)...
Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2019. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2018. Additionally, five members were...
Oncologists Urged to Be Proactive in Advising Patients to Reduce Risk of Alcohol-Related Cancers
A recently released ASCO statement summarizing extensive evidence linking alcohol use to an increased risk of several leading cancers, including breast, colon, and head and neck, called on oncologists “as front-line providers for cancer patients” to help patients reduce excessive alcohol use.1...
Seven Leaders Join MD Anderson Cancer Center Board of Visitors
The University of Texas MD Anderson Cancer Center Board of Visitors welcomed seven new members at its annual meeting in early November: Randy A. Foutch, Winell Herron, Cyvia Wolff, Isabella Arjona-Zappala, R. Stan Marek, Jr, Walker N. Moody, and Jerry Simon. The Board of Visitors is a...
Gemtuzumab Ozogamicin in CD33-Positive Acute Myeloid Leukemia
On September 1, 2017, gemtuzumab ozogamicin (Mylotarg) was approved for treatment for newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients aged ≥ 2 years.1,2 It may be used in combination...
Data Must Be Generated to Support Cross-Labeling of Combination Therapies for Cancer
Combinations of targeted therapies (triple, quadruple, or even more) are part of the future of cancer treatment, which means that traditional clinical trials will have to be streamlined and updated to enable greater flexibility and to extract adequate safety and efficacy data. Problems inherent in...
FDA Helps Streamline Approval Process for Supplemental Drug Indications
As researchers learn more about the natural history of cancers, as more drugs are effective for more types of the disease, and as the number and complexity of combination therapies increase, the more important it is that new drugs and permutations of old ones be available to patients. The U.S. Food ...
Slovenia’s First Medical Oncology Resident Reflects on His Career in a Rapidly Changing Field
Bostjan Seruga, MD, PhD, is a medical oncology consultant at the Insitute of Oncology Ljubljana and Associate Professor at the University of Ljubljana, Slovenia. He has published on barriers in global cancer research. The ASCO Post spoke with him recently about his career path, cancer care in...
Deadline Approaching: Give a Year-End Gift by December 31
The New Year is almost here—and what better way to close out 2017 than by donating to Conquer Cancer, ASCO’s affiliate organization? Your tax-deductible year-end gift will help fuel advances in prevention, treatment, and cures for all types of cancer. Give now at CONQUER.ORG/Year-End to end 2017...
Columbia and NewYork-Presbyterian Receive $700 Million Donation for Cancer Research and Care
Columbia University and NewYork-Presbyterian announced that Florence Irving and her late husband, Herbert Irving, have given $700 million to the two institutions to advance research and clinical programs for the treatment of cancer. The Irvings’ historic gift will have a profound impact on research ...
Exercise Counteracts Fatigue, Pain in Women With Advanced Breast Cancer
A SUPERVISED and individualized exercise program can reduce fatigue and pain while improving cardiovascular health and quality of life in women being treated for advanced breast cancer, according to research presented by Eduardo Oliveira, PhD, Professor of Exercise Physiology and Exercise Cancer...
Broadening the Evidence Base for Older Patients: FDA-ASCO Workshop Explores Emerging Strategies
In the not-so-distant past, clinical trials were considered an option only for the young and fit. Enrolling older people “used to be thought unethical,” said Janet Woodcock, MD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER), as she opened...
New Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology
KIMBERLY BLACKWELL, MD, one of the nation’s leading breast cancer researchers, will join Lilly Oncology as Vice President of Early Phase Development and Immuno-oncology as of March 12, 2018. Dr. Blackwell is currently Professor of Medicine and Assistant Professor of Radiation Oncology at Duke...
Alexander Fleming Would Have Loved Our Success With Cancer Immunotherapy
THE UNIVERSITY of Edinburgh Medical School was established in 1726 during the Scottish Enlightenment. As one of the oldest medical schools in the English-speaking world, it is interesting to reflect on the seminal contributions made centuries ago by several alumni that are still relevant to the...
Howard A. ‘Skip’ Burris III, MD, FACP, FASCO, Elected ASCO President for 2019–2020 Term
Howard A. “Skip” Burris III, MD, FACP, FASCO, a long-time member and volunteer, has been elected to serve as the President of ASCO for the term beginning in June 2019. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2018. Additionally, five...
ASH 2017: JULIET Trial: 6-Month Analysis of Tisagenlecleucel in Relapsed/Refractory DLBCL Shows Sustained Responses
Six months after receiving a single dose of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy that targets CD-19, high response rates persist among adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to findings reported by Schuster et al at...
Michael A. Caligiuri, MD, Named President of City of Hope National Medical Center
City of Hope announced that it has appointed Michael A. Caligiuri, MD, to a new executive leadership role as President of City of Hope National Medical Center and Physician-in-Chief. Dr. Caligiuri is a health-care visionary, renowned cancer researcher, and President of the American Association for ...
Untangling the Controversies of Hematopoietic Cell Transplantation
BOOKMARK Title: Hematopoietic Cell Transplants: Concepts, Controversies, and Future DirectionsEditors: Hillard M. Lazarus, MD; Robert Peter Gale, MD, PhD, DSc (hon), FACP; Armand Keating, MD, FRCP(C); Andrea Bacigalupo, MD; Reinhold Munker, MD; Kerry Atkinson, MBBS, MD, DTM&H, FRCP, FRACP; and...
Love Triumphs Amid a Battle With Cancer
BOOKMARK Title: The Red Devil: To Hell With Cancer—and BackAuthor: Katherine Russell RichPublisher: CrownDate Published: October 1999Price: $23.95, hardcover, 256 pages Over the past year or so, there have been several best-selling memoirs of people fighting and ultimately losing their battle with ...
Virginia Cancer Specialists and The US Oncology Network Welcome Stephanie Akbari, MD, FACS
Virginia Cancer Specialists, a practice within The US Oncology Network and a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients, has announced that Stephanie Akbari, MD, FACS, has joined the practice. Dr. Akbari, the first dedicated breast...
SABCS 2017: Combined Residual Risk Score Test and Predicting Breast Cancer Risk in Women Who Tested Negative for Hereditary Mutations
Results from a validation study to better define the risk of breast cancer in women of European ancestry who tested negative for a hereditary cancer mutation with a hereditary cancer risk test (myRisk Hereditary Cancer test) were reported earlier this week in a spotlight presentation at the 2017...
Born in Chicago, Lymphoma Specialist Sonali M. Smith, MD, Never Left the Windy City
Nationally recognized lymphoma expert Sonali M. Smith, MD, was born and reared in Chicago to a mother who was a pediatrician and allergist, and a father who was an engineer. Her parents were first-generation immigrants from India who placed the value of education second to none. “I became used to...
SABCS 2017: 2 Years of Extended Anastrozole Therapy Proved as Effective as 5 Years in Hormone Receptor–Positive Breast Cancer
Postmenopausal women with hormone receptor–positive breast cancer who took the aromatase inhibitor anastrozole for 2 years after an initial 5 years of adjuvant endocrine therapy received an equal benefit to those who took the drug for 5 additional years. The trial results suggest that a...
Honor a Loved One With a Gift to Conquer Cancer
This holiday season, fund breakthrough cancer research on behalf of someone you love. Visit CONQUER.ORG/Tribute-Gift to make a tax-deductible gift to Conquer Cancer, ASCO’s affiliate, and send an eCard or mailed notification of your donation. Your support will help fuel the brightest researchers...
New WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and Medeiros explore the recently updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
Follicular Lymphoma: Is the Road to Cure Paved With Gallium?
The roadside along the path to curing follicular lymphoma is riddled with the debris of failed cytotoxic regimens. For decades, clinical trials unsuccessfully pitted various chemotherapy combinations against each other. It took but a single, noncytotoxic molecule, rituximab (Rituxan), to forever...
Shifting Landscape of Oncology Drug Development and Approvals
Future oncology drug development and approvals will be faster and more efficient as well as take the patient experience more into account, said Richard Pazdur, MD, Director of the Oncology Center of Excellence at the U.S. Food and Drug Administration (FDA). The Center was established as part of...
Concurrent Palliative Care: Recommendations From the ASCO Clinical Practice Guideline
Updated in 2016, the ASCO clinical practice guideline on the integration of palliative care into standard oncology care provides evidence-based recommendations to oncology clinicians, patients, family and friend caregivers, and palliative care specialists about providing high-quality care for...
International Society of Geriatric Oncology Awards Leaders at 2017 Conference
The International Society of Geriatric Oncology (SIOG) Annual Conference took place November 9–11, 2017, in Warsaw, Poland. Over 350 delegates representing 41 countries attended the meeting, along with more than 60 faculty from 22 countries. Stuart Lichtman, MD, FACP, FASCO, SIOG President, and...
Managing Low-Dose CT Screening for Lung Cancer
As low-dose computed tomography (CT) screening for lung cancer has moved from clinical trials to clinical practice, management issues are growing more urgent for screening centers around the country: for instance, how to support referrals from and to other providers; how to ensure the quality of...
Durvalumab Therapy Improves Outcomes in Patients With Unresectable Stage III NSCLC
The PACIFIC study showed that the addition of the programmed cell death ligand 1 (PD-L1) inhibitor durvalumab (Imfinzi) following chemoradiotherapy for patients with unresectable stage III non–small cell lung cancer (NSCLC) dramatically improved progression-free survival compared with placebo....
CAR T-Cell Therapy Makes Further Inroads in Lymphoma and Myeloma
With the recent U.S. Food and Drug Administration (FDA) approvals of two chimeric antigen receptor (CAR) T-cell products, this novel approach seems to be moving into the mainstream. The approvals were tisagenlecleucel (also known as CTL019; Kymriah) for the treatment of pediatric B-cell acute...
